Form 4 ACADIA PHARMACEUTICALS For: Feb 23 Filed by: Schneyer Mark C.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'
February 28, 2024 6:15 AM ESTMizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "With investor focus on the Daybue launch, ACAD will likely trade down today. We would buy on weakness. Investors... More
